<DOC>
	<DOCNO>NCT00543374</DOCNO>
	<brief_summary>Protocol 610 enrol subject successfully achieve clinical benefit ( reduction CDAI least 100 point ) Protocol 603 . Protocol 610 evaluate length initial effect PROCHYMAL® adult human mesenchymal stem cell ability cell successfully re-induce clinical benefit .</brief_summary>
	<brief_title>Extended Evaluation PROCHYMAL® Adult Human Stem Cells Treatment-Resistant Moderate-to-Severe Crohn 's Disease</brief_title>
	<detailed_description>A significant number individual Crohn 's disease find relief exist steroidal , immunosuppressive , biologic therapy , force seek surgery drastic measure treatment . PROCHYMAL® adult human stem cell manufacture healthy , volunteer donor , extensively test , store available need . Human animal study show cell require donor-recipient matching . The cell may immunosuppressive heal benefit Crohn 's disease . The cell naturally migrate specifically sit inflammation , effect believe local self-limiting rather systemic . Protocol 610 extension study offer subject successfully achieve clinical benefit ( reduction CDAI least 100 point ) Protocol 603 .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Participation Osiris Protocol 603 , drop least 100 point CDAI Day 28 Substance abuse Failure receive full dose intervention Protocl 603</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>